Galecto Announces First Patient Dosed In An Investigator-Initiated Phase 2 Trial Of GB1211 In Combination With Pembrolizumab menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib).
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Galecto Inc. (GLTO) Reports Topline Results from MYLOX-1 Trial Demonstrated Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BOSTON, Sept. 26, 2023 Galecto, Inc. , a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a.